Although the fourth quarter of 2020 brought financial challenges for some health insurers due to surging coronavirus infections, the pharmacy-focused divisions of those publicly traded firms seemed to provide a universal bright spot.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.